ALK will initially focus on bringing neffy® to the markets in Europe and Canada, the world's second and third largest adrenaline autoinjector ("AAI”) markets. In both markets, the product can be added ...

ALK licenses rights to adrenaline nasal spray, neffy from ARS Pharma for emergency treatment of allergic reactions: Hørsholm, Denmark Tuesday, November 12, 2024, 12:00 Hrs [IST] ...

The U.S. Food and Drug Administration is taking the first step to remove an ingredient in non-prescription cold medicines ...

Phenylephrine is included in many cold and flu products, but a scientific panel last year found that it doesn't really do its ...

The FDA had proposed removing phenylephrine, a widely used ingredient to treat nasal congestion, from over-the-counter cold ...

Commercial launch of neffy® (epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by FDA; PDUFA target date set for March 6, 2025Exclusive ...

NDA for CARDAMYST™ in PSVT under review by FDA; PDUFA March 27, 2025MONTREAL and CHARLOTTE, N.C., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Milestone® (Nasdaq: MIST) today reported financial results for the ...

Tonix, known for its work in developing new treatments for central nervous system (CNS ... and Tosymra® (sumatriptan) nasal spray are prescription medicines used to treat acute migraine headaches with ...

Revenue: Total revenue was $2.1 million for the quarter ended September 30, 2024, comprised of $0.6 million in net product ...

but without a prescription. Pseudoephedrine in large quantities can be used to make methamphetamine. Last September, an FDA ...

Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the third quarter ended September 30, 2024 and provided ...

The FDA approved phenylephrine in the 1970s but it was used in more products in 2005 after pseudoephedrine was forced to be ...